| Thai T Do, MD | |
|
1011 Baldwin Park Blvd, Baldwin Park, CA 91706-5806 | |
| (626) 851-1011 | |
| Not Available |
| Full Name | Thai T Do |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Occupational Medicine |
| Location | 1011 Baldwin Park Blvd, Baldwin Park, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639240559 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | A45662 (California) | Primary |
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine fibroids (myoma) - a condition that affects millions of women worldwide.
Chromatrap, a business unit of Porvair Sciences, has announced that it will be the Lead Sponsor at the prestigious "Epigenetics in Drug Discovery" conference to be held in Cambridge, UK from 26th-27th January 2016.
Young girls who are hyperactive are more likely to get hooked on smoking, under-perform in school or jobs and gravitate towards mentally abusive relationships as adults, according to a joint study by researchers from the Université de Montréal and the University College London (UCL).
Laboratory studies by chemical engineers at UC Santa Barbara may lead to new experimental methods for early detection and diagnosis - and to possible treatments - for pathological tissues that are precursors to multiple sclerosis and similar diseases.
Asterias Biotherapeutics, Inc., a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one of the nation's top rehabilitation hospitals for spinal cord injury and brain injury, has commenced enrollment for the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thai T Do, MD 1011 Baldwin Park Blvd, Baldwin Park, CA 91706-5806 Ph: (626) 851-1011 | Thai T Do, MD 1011 Baldwin Park Blvd, Baldwin Park, CA 91706-5806 Ph: (626) 851-1011 |
News Archive
PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine fibroids (myoma) - a condition that affects millions of women worldwide.
Chromatrap, a business unit of Porvair Sciences, has announced that it will be the Lead Sponsor at the prestigious "Epigenetics in Drug Discovery" conference to be held in Cambridge, UK from 26th-27th January 2016.
Young girls who are hyperactive are more likely to get hooked on smoking, under-perform in school or jobs and gravitate towards mentally abusive relationships as adults, according to a joint study by researchers from the Université de Montréal and the University College London (UCL).
Laboratory studies by chemical engineers at UC Santa Barbara may lead to new experimental methods for early detection and diagnosis - and to possible treatments - for pathological tissues that are precursors to multiple sclerosis and similar diseases.
Asterias Biotherapeutics, Inc., a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one of the nation's top rehabilitation hospitals for spinal cord injury and brain injury, has commenced enrollment for the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI).
› Verified 8 days ago
Jodi L. Lipson-cassutt, DO Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 1011 Baldwin Park Blvd, Baldwin Park, CA 91706 Phone: 626-851-1011 |